Get the Stockscreener App
1.24
0.40%
-0.005
Tharimmune Inc stock is traded at $1.24, with a volume of 17,180.
It is down -0.40% in the last 24 hours and down -30.34% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$1.245
Open:
$1.25
24h Volume:
17,180
Relative Volume:
0.28
Market Cap:
$5.22M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.0976
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-17.00%
1M Performance:
-30.34%
6M Performance:
-36.73%
1Y Performance:
-61.61%
1-Day Range:
$1.21
$1.26
1-Week Range:
$1.21
$1.5274
52-Week Range:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.24 | 5.24M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Stock (THAR) Latest News
What risks could impact Tharimmune Inc. stock performanceFree Price Action Based Buy Opportunity List - Newser
What indicators show strength in Tharimmune Inc.Entry Timing Tracker with Alert Accuracy - Newser
Intrinsic Value of Tharimmune Inc. Stock: Is It Undervalued or OvervaluedVolume Confirmed Setup with Entry Confidence - Newser
How strong is Tharimmune Inc. company’s balance sheetExpert Picks Tips With High Returns - jammulinksnews.com
What are Tharimmune Inc. company’s key revenue driversDaily Trading Tracker For Fast Growth - jammulinksnews.com
When is Tharimmune Inc. stock expected to show significant growthTop Growth Insights With High Returns - jammulinksnews.com
Can a trend reversal in Tharimmune Inc. lead to recoverySecure Entry Point Finder with Analysis - Newser
Tharimmune Completes Private Placement Agreement - TipRanks
What is Tharimmune Inc. company’s growth strategyAI Powered Entry Points From AI Tools - jammulinksnews.com
How to track smart money flows in Tharimmune Inc.Long-Term Stock Growth Forecast Insights - Newser
Is Tharimmune Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWeekly Setup Summary for Risk Controlled Trades - Newser
Is Tharimmune Inc. Stock a Good Fit for Conservative InvestorsFree Low Risk Swing Trade Opportunity List - Newser
Is it the right time to buy Tharimmune Inc. stockWealth Building Planner With Proven Results - jammulinksnews.com
What makes Tharimmune Inc. stock price move sharplyLong-Term Trend Tracking and Signal Summary - Newser
Tharimmune Announces $1.74M Direct Public Offering - TipRanks
What are the technical indicators suggesting about Tharimmune Inc.Maximize gains with data-driven stock picks - jammulinksnews.com
Does Tharimmune Inc. stock perform well during market downturnsOutstanding capital appreciation - jammulinksnews.com
How many analysts rate Tharimmune Inc. as a “Buy”Exceptional growth trajectory - jammulinksnews.com
Is Tharimmune Inc. a growth stock or a value stockExceptional market performance - jammulinksnews.com
What are analysts’ price targets for Tharimmune Inc. in the next 12 monthsDiscover stocks with explosive potential - jammulinksnews.com
Why Tharimmune Inc. stock attracts strong analyst attentionHigh Yield Stock Selection - Newser
Has Tharimmune Inc. Stock Ever Crashed Historical Volatility ReviewPredictable Return Stock Picks - Newser
Tharimmune prices $1.74 million direct offering - MSN
What analysts say about Tharimmune Inc. stockExceptional market performance - Autocar Professional
Tharimmune Inc. Stock Analysis and ForecastOutstanding growth strategies - PrintWeekIndia
Will Tharimmune Inc. stock benefit from interest rate changesAccelerated wealth building - jammulinksnews.com
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants - Lancaster Eagle-Gazette
What drives Tharimmune Inc. stock priceExceptional market positioning - Autocar Professional
Clinical-Stage Biotech Tharimmune Raises $1.74M Through Strategic Stock Offering for Immunology Research - Stock Titan
iTolerance, Inc. Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - The Daily Jeffersonian
Is Tharimmune Inc. a good long term investmentBreakthrough stock performance - jammulinksnews.com
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):